Therapeutic area intelligence for Anticoagulation with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Rivaroxaban →

Recent signals(3)

ClinicalJuly 28, 2026

Study on VTE Prevention in Hip and Knee Arthroplasty Comparing Aspirin and Rivaroxaban

A clinical trial is comparing the efficacy of aspirin alone versus aspirin combined with rivaroxaban for VTE prevention in patients undergoing total hip and knee arthroplasty.

ClinicalJuly 9, 2026

SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients

The SINGLE-AF trial is assessing the efficacy of direct oral anticoagulants in patients with atrial fibrillation at intermediate stroke risk.

Clinical

June 14, 2026

Rivaroxaban Trial for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients

A clinical trial is proposed to evaluate the use of rivaroxaban for stroke prevention in hypertrophic cardiomyopathy patients with abnormal left atrial strain.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.